Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02635061 · ClinicalTrials.gov registry record · Phase 1
Selective HDAC6 Inhibitor ACY 241 in Combination With Nivolumab in Patients With Unresectable Non Small Cell Lung Cancer
A Phase 1 study, sponsored by Celgene.
- Terminated
- Registry status
- Phase 1
- Development phase
- 17
- Enrollment target
NCT02635061 is a Phase 1 study that was terminated before completion, run by Celgene. The registered enrollment target is 17 participants.
The verdict
NCT02635061, a Phase 1 study, was terminated before completion, sponsored by Celgene.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 17 participants
- Enrollment target
Study Summary
Determine the safety, tolerability, dose limiting toxicities (DLTs), and maximum tolerated dose (MTD) of ACY 241 in combination with nivolumab.
Interventions
- DRUG Nivolumab
- DRUG ACY-241
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2016-08-25 |
| Est. Completion | 2024-01-22 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02635061
The ClinicalTrials.gov registry entry for NCT02635061 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Celgene, which has 308 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Nivolumab is the first listed.
NCT02635061 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02635061 about?
NCT02635061 is a clinical study titled "Selective HDAC6 Inhibitor ACY 241 in Combination With Nivolumab in Patients With Unresectable Non Small Cell Lung Cancer". Determine the safety, tolerability, dose limiting toxicities (DLTs), and maximum tolerated dose (MTD) of ACY 241 in combination with nivolumab.
What is the current status of trial NCT02635061?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 17 participants. The study started on 2016-08-25. Estimated completion is 2024-01-22.
What interventions are being tested in trial NCT02635061?
The interventions under investigation include: Nivolumab (DRUG), ACY-241 (DRUG).
Who is sponsoring clinical trial NCT02635061?
This trial is sponsored by Celgene, which has 308 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.